{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:33:53Z","timestamp":1761557633378,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.sapharm.2022.05.013","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T21:53:27Z","timestamp":1653688407000},"page":"4009-4011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severity of visual hallucinations worsened with lisinopril despite receiving sedative hypnotic therapy or antipsychotic therapy: First case report"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0306-9954","authenticated-orcid":false,"given":"Mohamed A.","family":"Jalloh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Doroudgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.sapharm.2022.05.013_bib1","first-page":"26","article-title":"Visual hallucinations: differential diagnosis and treatment","volume":"11","author":"Teeple","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"unstructured":"Clinical Pharmacology Powered by ClinicalKey. Elsevier. Updated August 1, 2021. http:\/\/www.clinicalpharmacology-ip.com\/Forms\/login.aspx?ReturnUrl=%2fdefault.aspx. Accessed June 10, 2021.","key":"10.1016\/j.sapharm.2022.05.013_bib2"},{"issue":"4","key":"10.1016\/j.sapharm.2022.05.013_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jch.12063","article-title":"Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review","volume":"15","author":"Doane","year":"2013","journal-title":"J Clin Hypertens (Greenwich)."},{"unstructured":"Micromedex Solutions. Truven Health Analytics. http:\/\/micromedex.com\/. Accessed October 1, 2021.","key":"10.1016\/j.sapharm.2022.05.013_bib4"},{"key":"10.1016\/j.sapharm.2022.05.013_bib5","article-title":"Doctor, there's a fly in my soup! Angiotensin\u2010converting enzyme inhibitors, endogenous opioids and visual hallucinations","volume":"3","author":"Rabinowitz","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.sapharm.2022.05.013_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/pgmj.69.809.240","article-title":"Hallucinations as an adverse effect of angiotensin converting enzyme inhibition","volume":"69","author":"Haffner","year":"1993","journal-title":"Postgrad Med"},{"key":"10.1016\/j.sapharm.2022.05.013_bib7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/jgs.2000.48.11.1533","article-title":"Quinapril\u2010associated acute psychosis in an older woman","volume":"48","author":"Tarlow","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.sapharm.2022.05.013_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1176\/ajp.142.2.270a","article-title":"Reversal of captopril\u2010induced psychosis with naloxone","volume":"142","author":"Gillman","year":"1985","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.sapharm.2022.05.013_bib9","first-page":"8","article-title":"Swedish adverse reactions committee . Captopril \u2010 psychosis","volume":"50","year":"1988","journal-title":"Bull SADRAC"},{"key":"10.1016\/j.sapharm.2022.05.013_bib10","first-page":"83","article-title":"Visual hallucinations after quinapril","volume":"112","author":"Walker","year":"1999","journal-title":"N Z Med J"},{"issue":"1","key":"10.1016\/j.sapharm.2022.05.013_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0253-7613.125192","article-title":"A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions","volume":"46","author":"Belhekar","year":"2014","journal-title":"Indian J Pharmacol"},{"issue":"9","key":"10.1016\/j.sapharm.2022.05.013_bib12","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1097\/IJG.0000000000000712","article-title":"Ophthalmic timolol hallucinations: a case series and review of the literature","volume":"26","author":"Nanda","year":"2017","journal-title":"J Glaucoma"},{"issue":"4","key":"10.1016\/j.sapharm.2022.05.013_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ajh\/2.4.294","article-title":"Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs","volume":"2","author":"Cushman","year":"1989","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.sapharm.2022.05.013_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0022-3565(24)36641-8","article-title":"Almost complete protection from [Met5]-enkephalin-Arg6-Gly7-Leu8 (Met-enk-RGL) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon","volume":"281","author":"Hiranuma","year":"1997","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"2 Suppl","key":"10.1016\/j.sapharm.2022.05.013_bib15","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"issue":"10","key":"10.1016\/j.sapharm.2022.05.013_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0196-0644(05)81389-7","article-title":"Naloxone reversal of hypotension due to captopril overdose","volume":"20","author":"Varon","year":"1991","journal-title":"Ann Emerg Med"},{"issue":"2-3","key":"10.1016\/j.sapharm.2022.05.013_bib17","first-page":"551","article-title":"Effect of angiotensin converting enzyme inhibitor (captopril) on cerebral blood flow in hypertensive patients without a history of stroke","volume":"9","author":"Minematsu","year":"1987","journal-title":"Clin Exp Hypertens A"},{"issue":"3","key":"10.1016\/j.sapharm.2022.05.013_bib18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.STR.28.3.580","article-title":"Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke","volume":"28","author":"Dyker","year":"1997","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.sapharm.2022.05.013_bib19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.STR.0000136034.86144.e9","article-title":"Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke","volume":"35","author":"Hatazawa","year":"2004","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.sapharm.2022.05.013_bib20","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archinternmed.2009.175","article-title":"Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study","volume":"169","author":"Sink","year":"2009","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.sapharm.2022.05.013_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1159\/000177156","article-title":"Losartan and reversible psychosis","volume":"87","author":"Ahmad","year":"1996","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.sapharm.2022.05.013_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaneurol.2014.3367","article-title":"Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study","volume":"72","author":"Lin","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.sapharm.2022.05.013_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0039-6257(02)00414-9","article-title":"Complex visual hallucinations in the visually impaired: the Charles Bonnet syndrome","volume":"48","author":"Menon","year":"2003","journal-title":"Surv Ophthalmol"},{"issue":"3-4","key":"10.1016\/j.sapharm.2022.05.013_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1503\/cmaj.090049","article-title":"Charles Bonnet syndrome: visual loss and hallucinations","volume":"181","author":"Jackson","year":"2009","journal-title":"CMAJ"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741122001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741122001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:29:25Z","timestamp":1761557365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741122001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1551741122001772"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2022.05.013","relation":{},"ISSN":["1551-7411"],"issn-type":[{"type":"print","value":"1551-7411"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severity of visual hallucinations worsened with lisinopril despite receiving sedative hypnotic therapy or antipsychotic therapy: First case report","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2022.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}